APG Asset Management N.V. raised its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 40.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,802 shares of the medical research company’s stock after acquiring an additional 26,155 shares during the quarter. APG Asset Management N.V.’s holdings in Exact Sciences were worth $3,580,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Exact Sciences by 16.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company’s stock worth $6,160,000 after acquiring an additional 12,349 shares during the last quarter. Thompson Investment Management Inc. increased its stake in shares of Exact Sciences by 13.1% in the first quarter. Thompson Investment Management Inc. now owns 160,584 shares of the medical research company’s stock valued at $11,090,000 after buying an additional 18,595 shares during the period. Vanguard Group Inc. raised its holdings in Exact Sciences by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 17,559,751 shares of the medical research company’s stock valued at $1,299,070,000 after buying an additional 115,058 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Exact Sciences by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 22,687 shares of the medical research company’s stock worth $1,678,000 after buying an additional 1,020 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Exact Sciences by 5.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock worth $14,361,000 after acquiring an additional 10,356 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now owns 13,687 shares of the company’s stock, valued at approximately $958,090. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.36% of the company’s stock.
Exact Sciences Stock Performance
Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The company had revenue of $699.26 million for the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. Exact Sciences’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the business earned ($0.45) EPS. On average, research analysts anticipate that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently issued reports on EXAS shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Exact Sciences in a research note on Friday, September 13th. Benchmark reduced their price target on Exact Sciences from $91.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Piper Sandler raised their price objective on Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, September 12th. BTIG Research decreased their target price on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, June 26th. Finally, Raymond James restated a “market perform” rating on shares of Exact Sciences in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average target price of $77.77.
Read Our Latest Research Report on Exact Sciences
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
- Five stocks we like better than Exact Sciences
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Are Penny Stocks a Good Fit for Your Portfolio?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What Are Dividend Champions? How to Invest in the Champions
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS – Free Report).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.